Overview of Current Drug Delivery Methods Across the Blood-Brain Barrier for the Treatment of Primary Brain Tumors.

Abstract:

:Existing drug delivery methods have not led to a significant increase in survival for patients with malignant primary brain tumors. While the combination of conventional therapies consisting of surgery, radiotherapy, and chemotherapy has improved survival for some types of brain tumors (e.g., WNT medulloblastoma), other types of brain tumors (e.g., glioblastoma and diffuse midline glioma) still have a poor prognosis. The reason for the differences in response can be largely attributed to the blood-brain barrier (BBB), a specialized structure at the microvasculature level that regulates the transport of molecules across the blood vessels into the brain parenchyma. This structure hampers the delivery of most chemotherapeutic agents for the treatment of primary brain tumors. Several drug delivery methods such as nanoparticles, convection enhanced delivery, focused ultrasound, intranasal delivery, and intra-arterial delivery have been developed to overcome the BBB in primary brain tumors. However, prognosis of most primary brain tumors still remains poor. The heterogeneity of the BBB in primary brain tumors and the distinct vasculature of tumors make it difficult to design a drug delivery method that targets the entire tumor. Drug delivery methods that combine strategies such as focused ultrasound and nanoparticles might be a more successful approach. However, more research is needed to optimize and develop new drug delivery techniques to improve survival of patients with primary brain tumors.

journal_name

CNS Drugs

journal_title

CNS drugs

authors

Haumann R,Videira JC,Kaspers GJL,van Vuurden DG,Hulleman E

doi

10.1007/s40263-020-00766-w

subject

Has Abstract

pub_date

2020-11-01 00:00:00

pages

1121-1131

issue

11

eissn

1172-7047

issn

1179-1934

pii

10.1007/s40263-020-00766-w

journal_volume

34

pub_type

杂志文章,评审
  • Role of the melatonin system in the control of sleep: therapeutic implications.

    abstract::The circadian rhythm of pineal melatonin secretion, which is controlled by the suprachiasmatic nucleus (SCN), is reflective of mechanisms that are involved in the control of the sleep/wake cycle. Melatonin can influence sleep-promoting and sleep/wake rhythm-regulating actions through the specific activation of MT(1) (...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200721120-00004

    authors: Pandi-Perumal SR,Srinivasan V,Spence DW,Cardinali DP

    更新日期:2007-01-01 00:00:00

  • A Decade of Gabapentinoid Misuse: An Analysis of the European Medicines Agency's 'Suspected Adverse Drug Reactions' Database.

    abstract:INTRODUCTION:The gabapentinoids pregabalin and gabapentin are being increasingly prescribed for a range of clinical conditions. Recently, although gabapentinoids at therapeutic dosages may present with low addictive liability levels, cases of misuse and rising numbers of related fatalities have been reported. OBJECTIV...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.1007/s40263-016-0359-y

    authors: Chiappini S,Schifano F

    更新日期:2016-07-01 00:00:00

  • Biological markers of age-related memory deficits: treatment of senescent physiology.

    abstract::In humans, age-related memory impairments begin in mid-life and cognitive weakening continues with advancing age. An important aspect of defining memory decline is the distinction between dementia as a result of neurological diseases, such as Alzheimer's disease, and memory loss not specifically associated with diseas...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200620020-00006

    authors: Foster TC

    更新日期:2006-01-01 00:00:00

  • Calcium Channel Antagonists as Disease-Modifying Therapy for Parkinson's Disease: Therapeutic Rationale and Current Status.

    abstract::Parkinson's disease is a disabling hypokinetic neurological movement disorder in which the aetiology is unknown in the majority of cases. Current pharmacological treatments, though effective at restoring movement, are only symptomatic and do nothing to slow disease progression. Electrophysiological, epidemiological an...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-016-0393-9

    authors: Swart T,Hurley MJ

    更新日期:2016-12-01 00:00:00

  • The risk of stroke in patients with migraine and implications for migraine management.

    abstract::Assessing the risk of stroke in persons with migraine is complicated by the intricate relationship between these two conditions. Both migraine and stroke are common and co-morbidity may, in some cases, be coincidental. Given the overlap of clinical symptoms in stroke and migraine, each condition may also mimic the oth...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200519080-00004

    authors: Tietjen GE

    更新日期:2005-01-01 00:00:00

  • Lacosamide: a review of its use as adjunctive therapy in the management of partial-onset seizures.

    abstract::Lacosamide (Vimpat(®)) is a functionalized amino acid available orally (as a syrup or tablet) and as an intravenous infusion. It is believed to exert its antiepileptic effect by selectively enhancing the slow inactivation of voltage-gated sodium channels. Lacosamide is approved in several countries worldwide as an adj...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-013-0123-5

    authors: Hoy SM

    更新日期:2013-12-01 00:00:00

  • Treatment of epileptic encephalopathies.

    abstract::Epileptic encephalopathy is defined as a condition where the epileptic activity itself may contribute to the severe neurological and cognitive impairment seen, over and above that which would be expected from the underlying pathology alone. The epilepsy syndromes at high risk of this are a disparate group of condition...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-013-0041-6

    authors: McTague A,Cross JH

    更新日期:2013-03-01 00:00:00

  • Cognitive Efficacy of Pharmacologic Treatments in Multiple Sclerosis: A Systematic Review.

    abstract:INTRODUCTION:Cognitive impairment is prevalent and debilitating among persons with multiple sclerosis (MS). While many pharmacologic treatments have shown good efficacy in reducing clinical relapses, brain lesions, and improving certain physical symptoms, their efficacy for improving cognitive function is not well unde...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-020-00734-4

    authors: Chen MH,Goverover Y,Genova HM,DeLuca J

    更新日期:2020-06-01 00:00:00

  • Spotlight on risperidone in irritability associated with autistic disorder in children and adolescents.

    abstract::Risperidone (Risperdal), a psychotropic atypical antipsychotic agent, is thought to act via dopamine D(2) and serotonin 5-HT(2A) receptor antagonism. The clinical efficacy of oral risperidone in the treatment of bipolar mania and schizophrenia in adult patients is well established. In the US, risperidone is also appro...

    journal_title:CNS drugs

    pub_type: 评论,杂志文章

    doi:10.2165/00023210-200822030-00006

    authors: Scott LJ,Dhillon S

    更新日期:2008-01-01 00:00:00

  • Restoring Function to Dopaminergic Neurons: Progress in the Development of Cell-Based Therapies for Parkinson's Disease.

    abstract::There is escalating interest in cell-based therapies to restore lost dopamine inputs in Parkinson's disease. This is based upon the rationale that implanting dopamine progenitors into the striatum can potentially improve dopamine-responsive motor symptoms. A rich body of data describing clinical trials of previous cel...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.1007/s40263-020-00727-3

    authors: Henchcliffe C,Sarva H

    更新日期:2020-06-01 00:00:00

  • Ziprasidone.

    abstract::▴ Ziprasidone is a novel antipsychotic drug. It has high affinity for serotonin 5-HT(2) and dopamine D(2) receptors in vitro, with an 11-fold higher affinity for 5-HT(2) than for D(2) receptors, suggestive of a low potential for inducing motor disturbance [including extrapyramidal symptoms (EPS)].▴ The effects of zipr...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.2165/00023210-199708020-00006

    authors: Davis R,Markham A

    更新日期:1997-08-01 00:00:00

  • Long-Term Treatment of Restless Legs Syndrome (RLS): An Approach to Management of Worsening Symptoms, Loss of Efficacy, and Augmentation.

    abstract::Restless legs syndrome (RLS) is a common, frequently chronic, sensorimotor neurological disorder characterized by nocturnal leg dysesthesias and an irresistible urge to move the legs, usually resulting in sleep disturbance. Dopaminergic agonists, alpha-2-delta calcium-channel ligands, and opioids have all demonstrated...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-015-0250-2

    authors: Mackie S,Winkelman JW

    更新日期:2015-05-01 00:00:00

  • Novel IDH1-Targeted Glioma Therapies.

    abstract::Mutations in the isocitrate dehydrogenase (IDH) 1 gene are commonly found in human glioma, with the majority of low-grade gliomas harboring a recurrent point mutation (IDH1 R132H). Mutant IDH reveals an altered enzymatic activity leading to the synthesis of 2-hydroxyglutarate, which has been implicated in epigenetic m...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.1007/s40263-019-00684-6

    authors: Karpel-Massler G,Nguyen TTT,Shang E,Siegelin MD

    更新日期:2019-12-01 00:00:00

  • Pharmacological management of neuropathic pain following spinal cord injury.

    abstract::Spinal cord injury (SCI) has a number of severe and disabling consequences, including chronic pain, and around 40% of patients develop persistent neuropathic pain. Pain following SCI has a detrimental impact on the patient's quality of life and is a major specific healthcare problem in its own right. Thus far, there i...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200822060-00002

    authors: Baastrup C,Finnerup NB

    更新日期:2008-01-01 00:00:00

  • Antimicrobial Use in Patients with Dementia: Current Concerns and Future Recommendations.

    abstract::Infections are common in people with dementia, and antibiotic use is widespread, albeit highly variable, across healthcare settings and countries. The few studies conducted to date that consider the appropriateness of antibiotic prescribing specifically for people with dementia focus on people with advanced dementia a...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.1007/s40263-017-0427-y

    authors: Parsons C,van der Steen JT

    更新日期:2017-06-01 00:00:00

  • Correction to: Oral Disease-Modifying Treatments for Relapsing Multiple Sclerosis: A Likelihood to Achieve No Evidence of Disease Activity or Harm Analysis.

    abstract::NEDA was evaluated as the proportion of patients free of relapses, 3-month confirmed disability progression, and free of new or newly enlarging T2 lesion and Gadolinium enhancing lesions. ...

    journal_title:CNS drugs

    pub_type: 已发布勘误

    doi:10.1007/s40263-018-0595-4

    authors: Papadopoulos D,Mitsikostas DD

    更新日期:2019-01-01 00:00:00

  • Can Matching-Adjusted Indirect Comparison Methods Mitigate Placebo Response Differences Among Patient Populations in Adjunctive Trials of Brivaracetam and Levetiracetam?

    abstract:BACKGROUND AND OBJECTIVE:Patients with focal seizures recruited into adjunctive antiepileptic drug (AED) trials have become more refractory and severe over time; concurrently, placebo responses have increased. To attempt to account for heterogeneity among trials, propensity-score weighted patient-level data were used t...

    journal_title:CNS drugs

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s40263-017-0462-8

    authors: Swallow E,Fang A,Signorovitch J,Plumb J,Borghs S

    更新日期:2017-10-01 00:00:00

  • Selection criteria for the clinical use of the newer antiepileptic drugs.

    abstract::In recent years, several new antiepileptic drugs (AEDs) have been licensed: felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, tiagabine, topiramate, vigabatrin and zonisamide. These drugs have proven efficacy as add-on therapy in patients with difficult-to-treat partial epilepsy, as 20-50% of patients ...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200317060-00003

    authors: Deckers CL,Knoester PD,de Haan GJ,Keyser A,Renier WO,Hekster YA

    更新日期:2003-01-01 00:00:00

  • Use of the sustained pain-free plus no adverse events endpoint in clinical trials of triptans in acute migraine.

    abstract:OBJECTIVE:To assess the relationship between the sustained pain free (SPF) and adverse event (AE) rates associated with six oral serotonin 5-HT(1B/1D) receptor agonists (triptans) used for the treatment of acute migraine, employing data from a previous meta-analysis (that included almotriptan, eletriptan, naratriptan, ...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.2165/00023210-200721010-00006

    authors: Dodick DW,Sandrini G,Williams P

    更新日期:2007-01-01 00:00:00

  • Pharmacological management of postherpetic neuralgia.

    abstract::Postherpetic neuralgia, which occurs most typically in older persons, is one of the most common and serious complications of herpes zoster (or shingles). It is a chronic neuropathic pain syndrome and remains one of the most difficult pain disorders to treat. Known beneficial agents include antidepressants, antiepilept...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200317110-00001

    authors: Pappagallo M,Haldey EJ

    更新日期:2003-01-01 00:00:00

  • Cardiovascular effects and risk of syncope related to donepezil in patients with Alzheimer's disease.

    abstract:BACKGROUND:When otherwise unexplained, syncope in patients with Alzheimer's disease may be attributed to bradycardia caused by cholinesterase inhibitors. We studied prospectively the clinical events and cardiovascular changes occurring during treatment with donepezil in patients with Alzheimer's disease. METHODS:Conse...

    journal_title:CNS drugs

    pub_type: 临床试验,杂志文章

    doi:10.2165/00023210-200620050-00005

    authors: Bordier P,Garrigue S,Lanusse S,Margaine J,Robert F,Gencel L,Lafitte A

    更新日期:2006-01-01 00:00:00

  • Methylene Blue in the Treatment of Neuropsychiatric Disorders.

    abstract::Methylene blue is a long-established drug with complex pharmacology and multiple clinical indications. Its diverse mechanisms of action are most likely responsible for the large variety of its clinical effects. Of interest to psychiatrists, methylene blue has antidepressant, anxiolytic, and neuroprotective properties ...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-019-00641-3

    authors: Alda M

    更新日期:2019-08-01 00:00:00

  • Cost effectiveness of pharmacotherapy for the prevention of migraine: a Markov model application.

    abstract:BACKGROUND:There are few data about the cost effectiveness of prophylactic medications for migraine. Clinical trials have shown several preventive agents to be useful in reducing the frequency of migraine attack while having tolerable side effects. OBJECTIVE:To compare the cost effectiveness of adding preventive treat...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.2165/11531180-000000000-00000

    authors: Yu J,Smith KJ,Brixner DI

    更新日期:2010-08-01 00:00:00

  • Therapeutic monitoring of antiepileptic drugs during pregnancy and in the postpartum period: is it useful?

    abstract::As in all patient populations, epilepsy is common in pregnant women. Consequently, approximately 1 in 200 pregnancies is exposed to antiepileptic drugs (AEDs). Although exposure to AEDs in utero has been associated with an increased risk of major fetal malformations, most women with epilepsy require medication through...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200620100-00001

    authors: Adab N

    更新日期:2006-01-01 00:00:00

  • Mitoxantrone: a review of its use in multiple sclerosis.

    abstract::Mitoxantrone (Novantrone), a synthetic anthracenedione derivative, is an antineoplastic, immunomodulatory agent. Its presumed mechanism of action in patients with multiple sclerosis (MS) is via immunomodulatory mechanisms, although these remain to be fully elucidated. Intravenous mitoxantrone treatment improved neurol...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200418060-00010

    authors: Scott LJ,Figgitt DP

    更新日期:2004-01-01 00:00:00

  • Anticonvulsants for the treatment of alcohol withdrawal syndrome and alcohol use disorders.

    abstract::Alcoholic patients suffer from harmful allostatic neuroplastic changes in the brain causing an acute withdrawal syndrome upon cessation of drinking followed by a protracted abstinence syndrome and an increased risk of relapse to heavy drinking. Benzodiazepines have long been the treatment of choice for detoxifying pat...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-015-0240-4

    authors: Hammond CJ,Niciu MJ,Drew S,Arias AJ

    更新日期:2015-04-01 00:00:00

  • Lower IQ is associated with decreased clinical response to atomoxetine in children and adolescents with attention-deficit hyperactivity disorder.

    abstract:OBJECTIVES:Atomoxetine is commonly used to treat attention-deficit hyperactivity disorder (ADHD) in children with a broad range of cognitive abilities. We examined the association between level of cognitive functioning as determined by IQ and clinical response during treatment with atomoxetine. METHODS:The records of ...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.2165/11590450-000000000-00000

    authors: Mazzone L,Reale L,Mannino V,Cocuzza M,Vitiello B

    更新日期:2011-06-01 00:00:00

  • Pharmacotherapy for parents with attention-deficit hyperactivity disorder (ADHD): impact on maternal ADHD and parenting.

    abstract::Given the high heritability of the disorder, attention-deficit hyperactivity disorder (ADHD) is common among parents of children with ADHD. Parental ADHD is associated with maladaptive parenting, negative parent-child interaction patterns and a diminished response to behavioural parent training. We describe our previo...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.2165/11633910-000000000-00000

    authors: Chronis-Tuscano A,Stein MA

    更新日期:2012-09-01 00:00:00

  • Histamine and betahistine in the treatment of vertigo: elucidation of mechanisms of action.

    abstract::The aim of this review is to provide clinicians with a picture of the mechanisms by which: histamine and histaminergic agonists act on the vestibular system both peripherally and centrally; and histaminergic agonists and antagonists interfere with the recovery process after peripheral vestibular lesion. We have focuse...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200115110-00004

    authors: Lacour M,Sterkers O

    更新日期:2001-01-01 00:00:00

  • Discontinuation syndrome in dysthymic patients treated with selective serotonin reuptake inhibitors: a clinical investigation.

    abstract:OBJECTIVE:Many authors have reported discontinuation symptoms associated with selective serotonin reuptake inhibitors (SSRIs). The aim of this study was to investigate the incidence and characteristics of the discontinuation syndrome in patients who stopped treatment with the SSRIs paroxetine and fluoxetine under the u...

    journal_title:CNS drugs

    pub_type: 临床试验,杂志文章

    doi:10.2165/00023210-200216040-00006

    authors: Bogetto F,Bellino S,Revello RB,Patria L

    更新日期:2002-01-01 00:00:00